PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usua...